Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes (Q64266446)

12 December 2020

Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects

1 reference

12 December 2020

Dipeptidyl Peptidase IV in the Immune System. Effects of Specific Enzyme Inhibitors on Activity of Dipeptidyl Peptidase IV and Proliferation of Human Lymphocytes

1 reference

12 December 2020

Glucagon-like peptide-1 7-36: a physiological incretin in man.

1 reference

12 December 2020

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

1 reference

12 December 2020

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

1 reference

12 December 2020

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

1 reference

12 December 2020

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

1 reference

12 December 2020

Hamster preproglucagon contains the sequence of glucagon and two related peptides

1 reference

12 December 2020

Differential Processing of Proglucagon by the Subtilisin-like Prohormone Convertases PC2 and PC3 to Generate either Glucagon or Glucagon-like Peptide

1 reference

12 December 2020

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

1 reference

12 December 2020

Two molecular forms of peptide YY (PYY) are abundant in human blood: characterization of a radioimmunoassay recognizing PYY 1-36 and PYY 3-36

1 reference

12 December 2020

Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells

1 reference

12 December 2020

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

12 December 2020

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

1 reference

12 December 2020

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

1 reference

12 December 2020

Peptide YY does not inhibit glucose-stimulated insulin secretion in humans

1 reference

12 December 2020

Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig

1 reference

12 December 2020

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

12 December 2020

PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC.

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig.

1 reference

12 December 2020

Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1alpha (SDF-1alpha) and SDF-1beta are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage.

1 reference

12 December 2020

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

1 reference

12 December 2020

Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells

1 reference

12 December 2020

Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide

1 reference

12 December 2020

Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine.

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

1 reference

12 December 2020

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

12 December 2020

Regulation of pancreatic PC1 and PC2 associated with increased glucagon-like peptide 1 in diabetic rats

1 reference

12 December 2020

Molecular analysis of CD26-mediated signal transduction in T cells

1 reference

12 December 2020

Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose

1 reference

12 December 2020

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

1 reference

12 December 2020

Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide.

1 reference

12 December 2020

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

1 reference

12 December 2020

Effect of aging and diabetes on the enteroinsular axis

1 reference

12 December 2020

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

1 reference

12 December 2020

Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice

1 reference

12 December 2020

The role of dipeptidyl peptidase IV in the cleavage of glucagon family peptides: in vivo metabolism of pituitary adenylate cyclase activating polypeptide-(1-38).

1 reference

12 December 2020

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

1 reference

12 December 2020

Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells.

1 reference

12 December 2020

Role of caveolin and caveolae in insulin signaling and diabetes

1 reference

12 December 2020

Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion

1 reference

12 December 2020

Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors

1 reference

12 December 2020

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

1 reference

12 December 2020

CD26 up-regulates expression of CD86 on antigen-presenting cells by means of caveolin-1.

1 reference

12 December 2020

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

1 reference

12 December 2020

Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders

1 reference

12 December 2020

Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors

1 reference

12 December 2020

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus

1 reference

12 December 2020

Type 2 diabetes--therapy with dipeptidyl peptidase IV inhibitors

1 reference

12 December 2020

Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake.

1 reference

12 December 2020

Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes

1 reference

12 December 2020

Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus

1 reference

12 December 2020

A switch from prohormone convertase (PC)-2 to PC1/3 expression in transplanted alpha-cells is accompanied by differential processing of proglucagon and improved glucose homeostasis in mice.

1 reference

12 December 2020

Expression of caveolin-1 in human adipose tissue is upregulated in obesity and obesity-associated type 2 diabetes mellitus and related to inflammation

1 reference

12 December 2020

Stromal cell derived factor-1 (SDF-1)/CXCL12 attenuates diabetes in mice and promotes pancreatic beta-cell survival by activation of the prosurvival kinase Akt

1 reference

12 December 2020

Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects.

1 reference

12 December 2020

Revisiting an old acquaintance: CD26 and its molecular mechanisms in T cell function

1 reference

12 December 2020

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

1 reference

12 December 2020

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

1 reference

12 December 2020

Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction.

1 reference

12 December 2020

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses

1 reference

12 December 2020

Stromal cell-derived factor-1 promotes survival of pancreatic beta cells by the stabilisation of beta-catenin and activation of transcription factor 7-like 2 (TCF7L2).

1 reference

12 December 2020

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

1 reference

12 December 2020

The dipeptidyl peptidase IV family in cancer and cell biology.

1 reference

12 December 2020

The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha.

1 reference

12 December 2020

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Different modulation of dipeptidyl peptidase-4 activity between microvascular and macrovascular human endothelial cells

1 reference

12 December 2020

Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents.

1 reference

12 December 2020

Relationship between GLP-1 levels and dipeptidyl peptidase-4 activity in different glucose tolerance conditions

1 reference

12 December 2020

Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker

1 reference

12 December 2020

Upregulation of alpha cell glucagon-like peptide 1 (GLP-1) in Psammomys obesus—an adaptive response to hyperglycaemia?

1 reference

12 December 2020

Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studies

1 reference

12 December 2020

Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival

1 reference

12 December 2020

Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome

1 reference

12 December 2020

Processing of proglucagon to GLP-1 in pancreatic α-cells: is this a paracrine mechanism enabling GLP-1 to act on β-cells?

1 reference

12 December 2020

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells.

1 reference

12 December 2020

The increased dipeptidyl peptidase-4 activity is not counteracted by optimized glucose control in type 2 diabetes, but is lower in metformin-treated patients.

1 reference

12 December 2020

Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism

1 reference

12 December 2020

Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.

1 reference

12 December 2020

Plasma dipeptidyl peptidase 4 activity correlates with body mass index and the plasma adiponectin concentration in healthy young people.

1 reference

12 December 2020

A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets.

1 reference

12 December 2020

The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization

1 reference

12 December 2020

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

1 reference

12 December 2020

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

12 December 2020

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

12 December 2020

A PEGylated analog of the gut hormone oxyntomodulin with long-lasting antihyperglycemic, insulinotropic and anorexigenic activity

1 reference

12 December 2020

Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro

1 reference

12 December 2020

Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade

1 reference

12 December 2020

The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses

1 reference

12 December 2020

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

1 reference

12 December 2020

Quantification of intact and truncated stromal cell-derived factor-1α in circulation by immunoaffinity enrichment and tandem mass spectrometry

1 reference

12 December 2020

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

1 reference

12 December 2020

Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin

1 reference

12 December 2020

Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes

1 reference

12 December 2020

Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies

1 reference

12 December 2020

Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors

1 reference

12 December 2020

Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors.

1 reference

12 December 2020

Dipeptidyl peptidase-4 (DPP-4): Localization and activity in human and rodent islets

1 reference

12 December 2020

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

1 reference

12 December 2020

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

1 reference

12 December 2020

Localization of dipeptidyl peptidase-4 (CD26) to human pancreatic ducts and islet alpha cells.

1 reference

12 December 2020

Comparative review of dipeptidyl peptidase-4 inhibitors and sulphonylureas.

1 reference

12 December 2020

Drug development from the bench to the pharmacy: with special reference to dipeptidyl peptidase-4 inhibitor development

1 reference

12 December 2020

Reduced DPP4 activity improves insulin signaling in primary human adipocytes.

1 reference

12 December 2020

Effects of high glucose on caveolin-1 and insulin signaling in 3T3-L1 adipocytes

1 reference

12 December 2020

Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.

1 reference

12 December 2020

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

1 reference

12 December 2020

Pancreatic Safety of Sitagliptin in the TECOS Study

1 reference

12 December 2020

Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes.

1 reference

12 December 2020

Hepatic DPP4 DNA Methylation Associates With Fatty Liver.

1 reference

12 December 2020

Dipeptidyl peptidase-4 impairs insulin signaling and promotes lipid accumulation in hepatocytes

1 reference

12 December 2020

Altered circulating concentrations of active glucagon-like peptide (GLP-1) and dipeptidyl peptidase 4 (DPP4) in obese subjects and their association with insulin resistance.

1 reference

12 December 2020

The Role of Pancreatic Preproglucagon in Glucose Homeostasis in Mice.

1 reference

12 December 2020

Pancreatic α Cell-Derived Glucagon-Related Peptides Are Required for β Cell Adaptation and Glucose Homeostasis

1 reference

12 December 2020

Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes.

1 reference

12 December 2020

Differential Effects of Linagliptin on the Function of Human Islets Isolated from Non-diabetic and Diabetic Donors

1 reference

12 December 2020

Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure.

1 reference

12 December 2020

GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study

1 reference

12 December 2020

Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease

1 reference

12 December 2020

Metabolic regulation of GLP-1 and PC1/3 in pancreatic α-cell line

1 reference

12 December 2020

CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.

1 reference

12 December 2020

DPP-4 is expressed in human pancreatic beta cells and its direct inhibition improves beta cell function and survival in type 2 diabetes

1 reference

12 December 2020

Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes

1 reference

12 December 2020

Oxyntomodulin: Actions and role in diabetes

1 reference

12 December 2020

The safety of gliptins : updated data in 2018.

1 reference

12 December 2020

Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance.

1 reference

12 December 2020

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

12 December 2020

Insulin Secretion Depends on Intra-islet Glucagon Signaling

1 reference

12 December 2020

Circulating Levels of Soluble Dipeptidyl Peptidase-4 Are Dissociated from Inflammation and Induced by Enzymatic DPP4 Inhibition

1 reference

12 December 2020

Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial

1 reference

12 December 2020

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes

1 reference

12 December 2020

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

1 reference

12 December 2020